Lipella Pharmaceuticals Inc.
LIPO
$0.31
$0.0311.80%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -36.44% | -11.31% | 43.79% | -22.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -36.44% | -11.31% | 43.79% | -22.77% |
| Cost of Revenue | -31.12% | 19.65% | 17.91% | 133.88% | 25.61% |
| Gross Profit | 25.39% | -34.24% | -24.03% | -166.56% | -32.52% |
| SG&A Expenses | 12.21% | 52.59% | -10.98% | 42.00% | -21.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.24% | 32.58% | 6.87% | 91.09% | 5.41% |
| Operating Income | 12.68% | -42.47% | -9.05% | -98.92% | -7.57% |
| Income Before Tax | 13.19% | -41.51% | -9.62% | -109.28% | -9.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.19% | -41.51% | -9.62% | -109.28% | -9.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.19% | -41.51% | -9.62% | -109.28% | -9.14% |
| EBIT | 12.68% | -42.47% | -9.05% | -98.92% | -7.57% |
| EBITDA | 12.69% | -42.50% | -9.06% | -99.01% | -7.54% |
| EPS Basic | 78.64% | 68.76% | 51.42% | -46.38% | 29.85% |
| Normalized Basic EPS | 78.64% | 68.76% | 51.42% | -46.39% | 29.86% |
| EPS Diluted | 78.31% | 68.69% | 51.15% | -45.57% | 29.85% |
| Normalized Diluted EPS | 78.64% | 68.76% | 51.42% | -46.39% | 29.86% |
| Average Basic Shares Outstanding | 306.50% | 352.85% | 125.65% | 42.98% | 55.60% |
| Average Diluted Shares Outstanding | 306.50% | 352.85% | 125.65% | 42.98% | 55.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |